Commercial Revenues Are Likely in 2018 Despite Modest Delay in Filing
In a research report published Tuesday, Brean Capital analyst Jason Wittes assumed coverage on shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), with a Buy rating and price …
Shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) jumped nearly 27% Wednesday following the news of FDA approval of opioid-induced constipation (OIC)-fighting drug Oral Relister, invented to help …
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced results of operations for the second quarter and six months ended June 30, 2015.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced that it has entered into an exclusive worldwide licensing agreement with Johns Hopkins University for [18F]DCFPyL (“PyL”), a clinical-stage …
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative ways to target and treat cancer, announced today that the U.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced details of its planned Phase 3 clinical trial for 1404, a developmental stage small molecule designed to help visualize …
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) and Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced that Valeant submitted a New Drug Application to the U.
In a research note released today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) with an $11 price target, after …
